Patents by Inventor Christian Von Torne
Christian Von Torne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11913078Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: GrantFiled: October 27, 2020Date of Patent: February 27, 2024Assignee: MYRIAD INTERNATIONAL GMBHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Torne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20210123107Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: October 27, 2020Publication date: April 29, 2021Applicant: MYRIAD INTERNATIONAL GMBHInventors: Mareike DARTMANN, Inke Sabine FEDER, Mathias GEHRMANN, Guido HENNIG, Karsten WEBER, Christian VON TORNE, Ralf KRONENWETT, Christoph PETRY
-
Patent number: 10851427Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: GrantFiled: January 17, 2020Date of Patent: December 1, 2020Assignee: MYRIAD INTERNATIONAL GMBHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20200224281Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: January 17, 2020Publication date: July 16, 2020Applicant: MYRIAD INTERNATIONAL GMBHInventors: Mareike DARTMANN, Inke Sabine FEDER, Mathias GEHRMANN, Guido HENNIG, Karsten WEBER, Christian VON TÖRNE, Ralf KRONENWETT, Christoph PETRY
-
Patent number: 10577661Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: GrantFiled: August 11, 2016Date of Patent: March 3, 2020Assignee: MYRIAD INTERNATIONAL GMBHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20170067118Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: August 11, 2016Publication date: March 9, 2017Applicant: Sividon Diagnostics GmbHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20130065786Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: March 29, 2011Publication date: March 14, 2013Applicant: Sividon Diagnostics GmbHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Patent number: 8355874Abstract: The invention relates to a method for developing a biomarker for the prognosis of the result of a therapeutical treatment based on data obtained in clinical studies, data remaining unchanged by therapy being subdivided into diagnostic and genomic parameters and the marker being defined by a combination of parameters. The method according to the invention is characterized by specifying the maximum number of parameters for defining the marker and thus the maximum complexity of the system from the beginning and by carrying out the search for defining parameters by sequential combination of clinical parameters (=z parameters) and/or genomic parameters (=x parameters).Type: GrantFiled: December 11, 2006Date of Patent: January 15, 2013Assignee: Bayer Technology Services GmbHInventors: Andreas Schuppert, Rolf Burghaus, Christian Von Törne, Stephan Schwers, Udo Stropp, Harald Kallabis
-
Publication number: 20110172928Abstract: The present invention relates to methods for prediction of an outcome of neoplastic disease or cancer. More specifically, the present invention relates to a method for the prediction of breast cancer by determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CA12, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF.Type: ApplicationFiled: June 16, 2009Publication date: July 14, 2011Applicant: Sividon DiagnosticsInventors: Mathias Gehrmann, Udo Stropp, Karsten Weber, Christian Von Törne, Marcus Schmidt
-
Publication number: 20110166838Abstract: The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@,Type: ApplicationFiled: June 16, 2009Publication date: July 7, 2011Applicant: Sividon DiagnosticsInventors: Mathias Gehrmann, Ralf Kronenwett, Udo Stropp, Christian Von Törne, Karsten Weber
-
Publication number: 20110166845Abstract: The invention relates to a method for the quality assessment of nucleic acid amplification reactions which is based on a mathematical approach for the quality assessment of complete nucleic acid amplification reactions and comprises the following steps: a) Carrying out an amplification reaction for at least one nucleic acid target molecule, b)Collecting time-related data reflecting the course of the amplification reaction, c) Fitting these time-related data with a growth model equation comprising at least one parameter, d) Obtaining, from said fitting process, at least one value for the at least one parameter.Type: ApplicationFiled: July 16, 2009Publication date: July 7, 2011Applicant: SIVIDON DIAGNOSTICS GMBHInventors: Christian Von Törne, Mareike Assink, Udo Stropp
-
Publication number: 20090311700Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer in untreated breast cancer patients. More specific, the present invention relates to the prognosis of breast cancer based on measurements of the expression levels of marker genes in tumor samples of breast cancer patients. Marker genes are disclosed which allow for an accurate prognosis of breast cancer in patients having node negative, fast proliferating breast cancer.Type: ApplicationFiled: September 25, 2007Publication date: December 17, 2009Applicant: Siemens Healthcare Diagnositcs Inc.Inventors: Mathias Gehrmann, Christian von Törne
-
Publication number: 20090239223Abstract: The invention relates to methods and kits for the prediction of a likely outcome of chemotherapy in a cancer patient. More specifically, the invention relates to the prediction of tumour response to chemotherapy based on measurements of expression levels of a small set of marker genes. The set of marker genes is useful for the identification of breast cancer subtypes responsive to taxane based chemotherapy, such as e.g. a taxane-anthracycline-cyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-based) chemotherapy.Type: ApplicationFiled: July 6, 2007Publication date: September 24, 2009Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Mathias Gehrmann, Christian Von Törne
-
Publication number: 20090222387Abstract: The present invention relates to methods and compositions for the diagnosis, prognosis, and prediction of breast cancer. More specifically, the invention relates to classification of breast cancer tissue samples based on measuring the expression of a set of marker genes. The set is useful for the identification of clinically important breast cancer subtypes. Methods are disclosed for prediction, diagnosis and prognosis of breast cancer.Type: ApplicationFiled: June 14, 2006Publication date: September 3, 2009Inventors: Mathias Gehrmann, Christian Von Törne
-
Publication number: 20090208945Abstract: The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a SADR gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat statin induced adverse drug reactions (SADR), the polynucleotide is selected from the group comprising: SEQ ID 1-35 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for SADR gene polypeptide and with or without the SADR gene promoter sequence.Type: ApplicationFiled: December 19, 2006Publication date: August 20, 2009Applicant: SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS GMBHInventors: Stephan Schwers, Udo Stropp, Harald Kallabis, Andreas Schuppert, Rolf Burghaus, Christian Von Torne, Gerd Schmitz
-
Publication number: 20090130678Abstract: The present invention relates to the field of prognosis of a proliferative disease in a patient. More specifically, the present invention relates to methods for the identification of the likely outcome of breast cancer in a breast cancer patient. The invention also relates to methods for the identification of the likely outcome of breast cancer in a patient on the basis of the ERBB2 status of the patient and expression levels of immune genes in tumour tissue of said patient.Type: ApplicationFiled: November 23, 2006Publication date: May 21, 2009Applicant: SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS GMBHInventors: Mathias Gehrmann, Christian Von Torne
-
Publication number: 20090093689Abstract: The invention relates to a method for developing a biomarker for the prognosis of the result of a therapeutical treatment based on data obtained in clinical studies, data remaining unchanged by therapy being subdivided into diagnostic and genomic parameters and the marker being defined by a combination of parameters. The method according to the invention is characterized by specifying the maximum number of parameters for defining the marker and thus the maximum complexity of the system from the beginning and by carrying out the search for defining parameters by sequential combination of clinical parameters (=z parameters) and/or genomic parameters (=x parameters).Type: ApplicationFiled: December 11, 2006Publication date: April 9, 2009Applicant: BAYER TECHNOLOGY SERVICES GMBHInventors: Andreas Schuppert, Rolf Burghaus, Christian Von Torne, Stephan Schwers, Udo Stropp, Harald Kallabis